Construction of a nomogram to predict the survival of metastatic gastric cancer patients that received immunotherapy

• Published in: Frontiers in immunology Vol. 13; p. 950868
• Main Authors: Gou, Miaomiao, Qian, Niansong, Zhang, Yong, Wei, Lihui, Fan, Qihuang, Wang, Zhikuan, Dai, Guanghai
• Format: Journal Article
• Language: English
• Published: Frontiers Media S.A 26-09-2022
• Subjects: Immunology; immunotherapy; inflammation markers; metastatic gastric cancer; nomograms; predicting
• ISSN: 1664-3224; 1664-3224
• DOI: 10.3389/fimmu.2022.950868

Background
Immunotherapy has shown promising results for metastatic gastric cancer (MGC) patients. Nevertheless, not all patients can benefit from anti-PD-1 treatment. Thus, this study aimed to develop and validate a prognostic nomogram for MGC patients that received immunotherapy.
Methods
Herein, MGC patients treated with anti-PD-1 between 1 October 2016 and 1 June 2022 at two separate Chinese PLA General Hospital centers were enrolled and randomly divided into training and validation sets (186 and 80 patients, respectively). The nomogram was constructed based on a multivariable Cox model using baseline variables from the training cohort. Its predictive accuracy was validated by the validation set. The consistency index (C-index) and calibration plots were used to evaluate the discriminative ability and accuracy of the nomogram. The net benefit of the nomogram was evaluated using decision curve analysis (DCA). Finally, we stratified patients by median total nomogram scores and performed Kaplan–Meier survival analyses.
Results
We developed the nomogram based on the multivariate analysis of the training cohort, including four parameters: surgery history, treatment line, lung immune prognostic index (LIPI), and platelet-to-lymphocyte ratio (PLR). The C-index of the nomogram was 0.745 in the training set. The calibration curve for 1- and 2-year survival showed good agreement between nomogram predictions and actual observations. In the validation group, the calibration curves demonstrated good performance of the nomogram, with a C-index for overall survival (OS) prediction of 0.713. The OS of patients with a score greater than the median nomogram score was significantly longer than patients with a score lower or equal to the median (
p
< 0.001).
Conclusion
We constructed a nomogram to predict the outcomes of MGC patients that received immunotherapy. This nomogram might facilitate individualized survival predictions and be helpful during clinical decision-making for MGC patients under anti-PD-1 therapy.